NCT03381625 - Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

July 24, 2021

Study Completion Date

July 24, 2021

Conditions

PsoriasisAtopic Dermatitis

Interventions

DRUG

BMX-010

Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.

DRUG

Placebo

Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.

Trial Locations (10)

Juva Skin & Laser Center, New York

Coastal Carolina Research Center, Mt. Pleasant

Ciocca Dermatology, Miami

Dermatology Associates of Nashville, Knoxville

Dawes Fretzin Dermatology Group, Indianapolis

Presicion Research Institute, Houston

AboutSkin Dermatology & DermSurgery, Greenwood Village

Colorado Skin Care, Englewood

Apex Dermatology, Denver

Encino Research Center, Encino